FASN and prostate cancer: Wen et al. found that anti-androgen bicalutamide (Casodex) or enzalutamide MDV3100 had little inhibitory effect on FASN expression and FASN-mediated cell growth and invasion in prostate cancer cell lines C4-2 and LNCaP when the androgen concentration was 1 nM (Wen et al., 2016).